
































































Scandinavian Journal of Public Health,  1–12
https://doi.org/10.1177/14034948211048050
© Author(s) 2021
Article reuse guidelines: sagepub.com/journals-permissions
DOI: 10.1177/ 403 9 821 0 50
journals.sagepub.com/home/sjp
Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors 
for infection and associated symptoms in Geneva, Switzerland: a 
population-based study
AuDe RIchARD1,2 , AnIA WIsnIAk1,2, JAvIeR PeRez-sAez2,3,  
henRI GARRIsOn-DesAny3 , DusAn PetROvIc1,4, GIOvAnnI PIumAttI1,5, 
hélène BAyssOn1,6, AttIlIO PIcAzIO1, FRAncescO PennAcchIO1,  
DAvID De RIDDeR1,6, FRAnçOIs chAPPuIs6,7, nIcOlAs vuIlleumIeR8,9,  
nIcOlA lOW10, sAmIA huRst11, IsABellA eckeRle12,13,  
AntOIne FlAhAult2,6,7, lAuRent kAIseR9,12,14, AnDReW s. AzmAn2,3,  
IDRIs GuessOus1,6 & sIlvIA stRInGhInI1,4,6
1Division of Primary Care, Geneva University Hospitals, Switzerland, 2Institute of Global Health, University of Geneva, 
Switzerland, 3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA, 4University Centre 
for General Medicine and Public Health (UNISANTE), University of Lausanne, Switzerland, 5Faculty of BioMedicine, 
Università della Svizzera Italiana, Switzerland, 6Department of Health and Community Medicine, University of Geneva, 
Switzerland, 7Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Switzerland, 8Division 
of Laboratory Medicine, Geneva University Hospitals, Switzerland, 9Department of Medicine, University of Geneva, 
Switzerland, 10Institute of Social and Preventive Medicine, University of Bern, Switzerland, 11Institute for Ethics, History, 
and the Humanities, University of Geneva, Switzerland, 12Geneva Center for Emerging Viral Diseases and Laboratory of 
Virology, Geneva University Hospitals, Switzerland, 13Department of Microbiology and Molecular Medicine, University of 
Geneva, Switzerland, and 14Division of Infectious Diseases, Geneva University Hospitals, Switzerland
the first and second and final two authors contributed equally to this work.
For the SEROCOV-POP study group: silvia stringhini, Idris Guessous, Andrew s. Azman, hélène Baysson, 
Prune collombet, matilde D’Asaro-Aglieri Rinella, David De Ridder, Paola d’Ippolito, yaron Dibner, nacira el 
merjani, natalie Francioli, marion Frangville, kailing marcus, chantal martinez, natacha noël, Francesco 
Pennacchio, Dusan Petrovic, Attilio Picazio, Alborz Pishkenari, Giovanni Piumatti, Jane Portier, caroline Pugin, 
Barinjaka Rakotomiaramanana, Aude Richard, lilas salzmann-Bellard, stephanie schrempft, maría-eugenia 
zaballa, zoé Waldmann, Ania Wisniak, Alioucha Davidovic, Joséphine Duc, Julie Guérin, Fanny lombard, 
manon Will, Antoine Flahault, Isabelle Arm vernez, Olivia keiser, loan mattera, magdalena schellongova, 
laurent kaiser, Isabella eckerle, Pierre lescuyer, Benjamin meyer, Géraldine Poulain, nicolas vuilleumier, 
sabine yerly, François chappuis, sylvie Welker, Delphine courvoisier, laurent Gétaz, mayssam nehme, 
Febronio Pardo, Guillemette violot, samia hurst, Philippe matute, Jean-michel maugey, Didier Pittet, Arnaud 
G. l’huillier, klara m. Posfay-Barbe, Jean-François Pradeau, michel tacchino, Didier trono
Abstract
Aims: to assess sARs-cov-2 seroprevalence over the first epidemic wave in the canton of Geneva, switzerland, as well as 
risk factors for infection and symptoms associated with IgG seropositivity. Methods: Between April and June 2020, former 
participants of a representative survey of the 20–74-year-old population of canton Geneva were invited to participate in the 
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study, along with household members aged over 5 years. Blood samples were tested for anti-sARs-cov-2 immunoglobulin G. 
Questionnaires were self-administered. We estimated seroprevalence with a Bayesian model accounting for test performance 
and sampling design. Results: We included 8344 participants, with an overall adjusted seroprevalence of 7.8% (95% credible 
interval 6.8–8.9). seroprevalence was highest among 18–49 year-olds (9.5%), and lowest in 5–9-year-old children (4.3%) 
and individuals >65 years (4.7-5.4%). Odds of seropositivity were significantly reduced for female retirees and unemployed 
men compared to employed individuals, and smokers compared to non-smokers. We found no significant association 
between occupation, level of education, neighborhood income and the risk of being seropositive. the symptom most strongly 
associated with seropositivity was anosmia/dysgeusia. Conclusions: Anti-SARS-CoV-2 population seroprevalence 
remained low after the first wave in Geneva. Socioeconomic factors were not associated with seropositivity in 
this sample. the elderly, young children and smokers were less frequently seropositive, although it is not clear 
how biology and behaviours shape these differences.
Keywords: SARS-CoV-2, COVID-19, population-based survey, seroprevalence, socioeconomic risk factors
Introduction
seroprevalence studies around the world have estab-
lished that only a small proportion of the population 
had been infected by sARs-cov-2 towards the end 
of the first wave in spring 2020, with most seropreva-
lence estimates ranging from less than 0.1 to more 
than 20%, depending on the setting and targeted 
populations [1–3]. Preliminary results from the first 
5 weeks of our 12-week population-based serosurvey 
conducted in the canton of Geneva, switzerland, in 
April and may, showed a weekly seroprevalence 
between 4.8% and 10.9% [4]. Regions with similar 
clinical incidence rates in France, Italy and spain 
showed similar results [5–7], while the least affected 
regions in spain and France showed seroprevalences 
of less than 3% [5–8].
socioeconomic risk factors for cOvID-19 such as 
low income, social deprivation and overcrowded living 
conditions have been identified in several studies 
based on molecular testing [9–13]. however, some of 
those studies included only hospitalised patients or 
individuals with severe cOvID-19. In addition, data 
on confirmed cOvID-19 cases are influenced by test-
ing policies and comprise only a minority of the whole 
infected population. serosurveys have the potential to 
assess the real extent of an outbreak in a given geo-
graphical region and provide information on risk fac-
tors, transmission and infection fatality rates without 
relying on clinical surveillance and virological confir-
mation. nevertheless, only a few population-based 
serostudies have assessed biological and socioeco-
nomic risk factors for seropositivity. these have gener-
ally highlighted significant relationships between 
Black, Asian and hispanic ethnicity, adult age (vary-
ing across studies), living in a deprived or dense area 
and large household size, and the risk of being sero-
positive [5–8, 14, 15]. While working in the healthcare 
field or essential services has been shown to be associ-
ated with a higher risk of seropositivity [6, 7, 14, 16], 
other individual factors such as education level and 
occupational category are rarely described. serosurveys 
can also provide a means to quantify the full spectrum 
of symptoms associated with sARs-cov-2, including 
mild and asymptomatic infections.
In switzerland, the first cases of cOvID-19 were 
recorded at the end of February 2020, followed by a 
first epidemic wave that took place during march 
and April 2020 [17]. strict non-pharmaceutical 
measures started on 16 march and were progres-
sively relaxed from 27 April 2020 when a total of 
29,313 cases and 427 deaths had been reported in 
the country [18]. In this study, we describe the age-
specific seroprevalence of anti-sARs-cov-2 anti-
bodies between April and June 2020 in Geneva, 
switzerland, and examine risk factors for and symp-
toms associated with seropositivity.
Methods
Study design and participants
seROcov-POP is a population-based repeated cross-
sectional observational seroprevalence study. We 
recruited participants between 6 April and 30 June 
2020. the recruitment strategy and serological data 
collection have previously been described in detail [4]. 
Briefly, participants were invited progressively by 
email and postal mail from the study population of a 
yearly health survey called Bus santé [19], which is 
representative of the 20–74-year-old population of 
canton Geneva. Participants were invited to bring 
members of their household aged 5 years and older. 
each person participated only once (one round). Of 
note, during the study period, the country was initially 
under lockdown; then, measures were progressively 
relaxed in three consecutive periods [20]. Written 
informed consent was obtained from all individual 
participants included in the study and from legal 
guardians for children under 18 years of age. the 
study protocol was approved by the cantonal Research 
ethics commission of Geneva, switzerland (ceR16-




SARS-CoV-2 seroprevalence, risk factors and associated symptoms  3
Laboratory analysis
Anti-sARs-cov-2 immunoglobulin G (IgG) serolog-
ical status was assessed using a commercially available 
enzyme-linked immunosorbent assay (elIsA) 
(euroimmun; lübeck, Germany #eI 2606-9601 G) 
targeting the s1 domain of the spike protein. We used 
the manufacturer’s recommended cut-off for positiv-
ity (⩾1.1), with a reported sensitivity of 93% and a 
specificity of 100% estimated in a diagnostic valida-
tion study conducted in the same lab as these analyses 
[21]. We tested all serum with an elIsA IgG ratio of 
0.5 or greater with an immunofluorescence assay 
(IFA) and classified individuals with results from this 
test (when performed) in sensitivity analyses.
Survey questions and coding
Participants could choose to fill in the study question-
naire online at home or complete it at the study site on a 
tablet computer or on paper. Questionnaires included 
items about sociodemographic characteristics, symp-
toms, exposure to sARs-cov-2-infected individuals 
and preventive behaviours in relation to the epidemic. 
sociodemographic variables included age, sex, employ-
ment status, professional occupation, professional 
changes due to the pandemic and educational level. 
educational level was based on the national swiss sys-
tem, with ‘mandatory education’ applying to all children 
aged 4–14 years, ‘secondary education’ corresponding 
to high school (15–18 years) and ‘university’ corre-
sponding to undergraduate and postgraduate studies.
Participants were also asked to self-identify their 
occupational sector and profession. We mapped this 
information using the european socioeconomic clas-
sifications (esecs). From the 10 levels of classifica-
tion, in order to maintain power, this was reduced to 
eight categories: (a) professional/manager (esec 
1–2); (b) higher grade white-collar workers (esec 2); 
(c) independent workers (esec 4–5); (d) lower grade 
white-collar workers(esec 7); (e) blue-collar, skilled, 
semi-skilled and non-skilled workers (esec 6, 8, 9); 
(f) other full-time workers to whom the esec catego-
ries were not applicable; as well as from esec class 
10; (g) students or retirees; and (h) unemployed.
Participants were asked to self-report all symp-
toms unrelated to a known chronic condition experi-
enced since January 2020, and to specify if these 
appeared as part of one or several distinct episodes. 
We defined participants as asymptomatic if they did 
not report any symptoms. Data were also collected 
on chronic health conditions, smoking status and 
height and weight for body mass index (BmI) calcu-
lation. the full study questionnaire is provided in the 
supplemental material.
Other data sources
Data on individual-level income was not collected in 
the questionnaire. however, we used data from the 
canton of Geneva to determine the median income 
for a single individual residing in participants’ neigh-
bourhoods. We grouped gross income into three cat-
egories defined as less than 37,000 chF/year (70% 
of the median income), 37,000–68,000 chF/year 
and more than 68,000 chF/year (~130% of the 
median income) [22].
Statistical analysis
We estimated the overall 12-week seroprevalence using 
a Bayesian logistic regression model accounting for test 
performance, sex, age as well as within household infec-
tion clustering, as previously described [4]. In our pri-
mary analyses, we used IgG elIsA results only to 
classify seropositivity, and performed post-stratification 
to obtain population-wide seroprevalence as well as by 
age and sex classes. As a sensitivity analysis, we used the 
IFA results for all participants tested with this assay. 
models were implemented in the stan probabilistic 
programming language. Details are provided in the 
supplemental material. Weekly crude proportions of 
seropositivity with binomial confidence intervals (cIs) 
were also calculated.
For socioeconomic and lifestyle risk factors, we 
limited our analysis to participants 18 years of age or 
older, resulting in a final analytical sample of 7442 
participants. estimated marginal proportions were 
adjusted for age and sex, with significance testing 
using the tukey method [23] for comparing esti-
mates between seronegative and seropositive groups. 
to test for association between sociodemographic, 
lifestyle and health-related risk factors and serologi-
cal status, we used mixed effect logistic models 
including a household-level random effect, except for 
the area-level income analysis. to understand the 
sensitivity of our results to missing data, we con-
ducted multilevel multiple imputation by chained 
equations using 10 datasets with 30 iterations across 
the dataset and re-ran our primary analyses.
chi-square tests were used to compare the fre-
quencies of individual symptoms between IgG sero-
positive and seronegative individuals. using logistic 
regression models, we estimated odds ratios (ORs) 
and 95% cIs for IgG seropositivity according to the 
presence of each symptom in the overall study sam-
ple and stratified by age groups. As a sensitivity anal-
ysis, we re-ran the logistic regression on individuals 
presenting only one symptomatic episode. to take 
into account the co-occurrence of symptoms, we fit 
multivariable logistic regression models to estimate 
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sex-adjusted and mutually adjusted ORs. the 
absence of a symptom was defined as the reference 
value for each symptom, while for the asymptomatic 
variable, not being asymptomatic was considered the 
reference value. Analyses were done using R statisti-
cal software version 4.0.3 [24].
Results
Between 6 April and 30 June 2020, we enrolled 8344 
participants between the ages of 5 and 94 years (902 
children <18 years), with a mean age of 46.9 years. 
the study sample included 4379 former Bus santé 
participants and 3965 household members, with a 
42% participation rate of all people invited by email 
(supplemental Figure 1).
compared with the population of the canton of 
Geneva, in seROcov-POP, the 50–74 years age 
group was overrepresented (46.6% vs. 27.4%), while 
the 5–9, 20–49 and 75 years and over age groups 
were slightly underrepresented. seROcov-POP 
participants also had generally higher levels of educa-
tion than the Geneva population, with more partici-
pants having received a tertiary education (57.7% vs. 
39.3%), and fewer having attended mandatory school 
only (6.8% vs. 28.1%) (supplemental table 1).
Seroprevalence and relative risk of seropositivity 
by age and sex
sARs-cov-2 seroprevalence over the study period was 
7.8% (95% credible interval (crI) 6.8–8.9, table I). 
the seroprevalence first increased from 7.1% (95% 
crI 5.5–8.7) to 9.0% (95% crI 7.5–10.5) between the 
first and second month, before decreasing again to 
7.1% (95% crI 5.7–8.5) in the third month (table I).
men were 22% (95% crI 6–40%) more likely to 
be seropositive than women. seroprevalence was 
highest in the 18–49 years age group (9.5%, 95% crI 
8.1–10.9) and lowest in children under 10 years 
(4.3%, 95% crI 2.2–7.0) and the elderly aged 75 
years and older (4.7%, 95% crI 2.8–7.0).
Socioeconomic, lifestyle and health-related risk 
factors
After adjusting for age and sex, there was a signifi-
cant difference in the distribution of seropositive par-
ticipants according to employment status (table II), 
with lower odds of being seropositive in female retir-
ees (OR 0.46, 95% cI 0.23–0.93) and unemployed 
men (OR 0.35, 95% cI 0.13–1.0) compared to 
employed individuals of the same sex. however, we 
did not observe any significant association between 
occupational category, educational level, area-based 
income and seropositivity.
Overall, 67.8% of the participants reported some 
change in work linked to the cOvID-19 epidemic, 
such as working remotely (43.0%), taking a sick leave 
(1.0%) or becoming unemployed (3.3%). sixteen 
out of 48 individuals who took sick leave were sero-
positive, suggesting that cOvID-19 had been 
responsible for up to one-third of all sick leaves dur-
ing the first wave.
there seemed to be an association of education 
with seropositivity in women, with a tendency 
towards increasing odds of seropositivity from man-
datory schooling only (OR 1.6, 95% cI 0.40–6.6) to 
table I. seroprevalence estimates and relative risk of sARs-cov-2 seropositivity (N=8344).




Relative risk (95% 
credible interval)
P value
 Positive negative  
Age group, years  
<10 (n=274) 9 (3.3%) 265 (96.7%) 4.3 (2.2–7.0) 0.44 (0.22–0.72) <0.001
10–17 (n=628) 50 (8.0%) 578 (92.0%) 7.9 (5.9–10.3) 0.83 (0.62–1.09) 0.1752
18–49 (n=3108) 278 (9.0%) 2830 (91.1%) 9.5 (8.1–10.9) 1 (ref) –
50–64 (n=2694) 180 (6.7%) 2514 (93.3%) 7.5 (6.2–8.8) 0.79 (0.65–0.94) 0.0076
65–74 (n=1196) 56 (4.7%) 1140 (95.3%) 5.4 (4.0–7.0) 0.57 (0.42–0.76) <0.001
>75 (n=444) 17 (3.8%) 427 (96.2%) 4.7 (2.8–7.0) 0.50 (0.29–0.75) 0.0012
sex  
Female (n=4465) 285 (6.4%) 4180 (93.6%) 7.0 (6.0–8.1) 1 (ref) –
male (n=3879) 305 (7.9%) 3574 (92.1%) 8.7 (7.4–10.0) 1.2 (1.1–1.4) 0.007
month  
April (n=1939) 130 (6.7%) 1809 (93.3%) 7.1 (5.5–8.7) 0.052
may (n=2997) 244 (8.1%) 2753 (91.9%) 9.0 (7.5–10.5) –
June (n=3408) 216 (6.3%) 3192 (93.7%) 7.1 (5.7–8.5) 0.028
Overall (n=8344) 590 (7.1%) 7754 (92.9%) 7.8 (6.8–8.9) – –
acalculated using a Bayesian logistic regression model accounting for test performance, sex and household clustering.
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university level (OR 3.0, 95% cI 0.92–9.9), com-
pared to women with a doctoral education.
We observed a gradient in seroprevalence between 
never smokers (8.2%), former smokers (6.6%) and 
current smokers (4.2%). however, only current 
smokers were significantly less likely to be seroposi-
tive compared to never smokers (OR 0.36, 95% cI 
0.23–0.55). there was no significant association 
between chronic health conditions and seropositivity. 
underweight individuals seemed to have decreased 
odds of seropositivity compared to individuals with a 
normal BmI (OR 0.57, 95% cI 0.10–1.04), although 
this trend was mostly apparent in men (OR 0.16, 
95% cI 0.02–1.2 vs. 0.74 in women, 95% cI 0.37–
1.5). On the other hand, obese women tended to 
have higher odds of seropositivity compared to 
women with a normal BmI (OR 1.9, 95% cI 0.95–
3.7), while there seemed to be no difference in male 
participants (OR 0.76, 95% cI 0.39–1.5).
A history of close contact with a sARs-cov-2-
infected person increased the odds of seropositivity 
nearly fivefold (OR 4.8, 95% cI 3.8–6.0).
Symptoms reported over one or more episodes
the symptoms most frequently reported by seropos-
itive participants were fatigue (57% of seropositive 
participants), headache (52%), sneezing and/or rhi-
norrhea (48%), fever (46%), cough (46%), anosmia 
and/or dysgeusia (44%), and myalgia and/or arthral-
gia (43%) (table III). seronegative individuals most 
frequently reported sneezing/rhinorrhea (32%), 
while only 3% reported loss of taste or smell. thirteen 
per cent of seropositive participants reported no 
symptoms, versus 43% of seronegative participants. 
not reporting any symptoms during the study period 
reduced by five the odds of being seropositive.
We observed age variations in the symptomatology 
associated with being seropositive. In children, anos-
mia and/or dysgeusia (OR 16.0, 95% cI 7.0–36.2), 
cough and/or fever (OR 1.8, 95% cI 1.1–3.1) and sys-
temic symptoms (OR 1.9, 95% cI 1.0–3.2) were the 
groups of symptoms most strongly associated with 
seropositivity (Figure 1). On the contrary, among par-
ticipants 65 years and older, dyspnea (OR 4.5, 95% cI 
2.4–7.8), digestive symptoms (OR 3.1, 95% cI 1.7–
5.2) and upper airways symptoms (OR 2.5, 95% cI 
1.6–4.9) were more strongly associated with seroposi-
tivity than in the other age categories, although cIs 
overlap. In all age categories, those not reporting symp-
toms were less likely to be seropositive, although we 
observed a stronger association in the 18–64 years (OR 
0.17, 95% cI 0.12–0.23) and over 65 years (OR 0.23, 
95% cI 0.12–0.39) age groups than in children (OR 
0.55, 95% cI 0.30–0.97).
In the multivariate analysis with co-adjustment of 
symptoms we observed that nausea and/or vomiting, 
abdominal pain and a sore throat were negatively 
associated with being seropositive (supplemental 
table 11).
Results for seroprevalence, risk factor and symptom 
analyses were mostly consistent when using the IFA 
confirmatory test (supplemental tables 3, 10, 13 and 
14). the symptom analysis was also generally similar 
when considering only participants with only one 
symptomatic episode (supplemental tables 15 and 16).
table III. Frequency of symptoms reported in all age groups.
symptom sARs-cov-2 IgG test result P value
Positive (N=590)a negative (N=7754)b  
Fatigue 332 (57%) 1787 (23%) <0.001
headache 308 (52%) 1936 (25%) <0.001
sneezing/rhinorrhea 284 (48%) 2468 (32%) <0.001
Fever 272 (46%) 1136 (15%) <0.001
cough 270 (46%) 1790 (23%) <0.001
Anosmia/dysgeusia 257 (44%) 233 (3.0%) <0.001
myalgia/arthralgia 252 (43%) 1160 (15%) <0.001
sore throat 200 (34%) 1786 (23%) <0.001
Dyspnea 131 (22%) 577 (7.5%) <0.001
loss of appetite 126 (21%) 323 (4.2%) <0.001
Diarrhoea 121 (21%) 749 (9.8%) <0.001
Abdominal pain 65 (11%) 527 (6.9%) <0.001
nausea/vomiting 55 (9.4%) 374 (4.9%) <0.001
Other symptoms 18 (3.1%) 181 (2.4%) 0.4
Asymptomatic 77 (13%) 3272 (43%) <0.001
athree missing values not included.
b107 missing values not included. these participants had missing values for all symptoms, as they did not fill in the symptoms question-
naire.
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Discussion
this study conducted between April and June 2020 
confirms preliminary results showing that fewer than 
10% of the population of the canton of Geneva had 
developed anti-sARs-cov-2 antibodies over the 
course of the first epidemic wave [4]. consistent with 
our previously published interim analysis, individuals 
aged under 10 years and over 65 years, as well as 
women, had the lowest risk of being seropositive. We 
did not identify clear associations between socioeco-
nomic variables and serological status. smoking 
appeared to reduce the odds of being seropositive, 
while no significant associations were found with 
other lifestyle and health-related risk factors. the 
symptom most strongly associated with seropositivity 
was anosmia/dysgeusia, followed by systemic symp-
toms such as loss of appetite, fever, fatigue and myal-
gia and/or arthralgia.
the average seroprevalence of 7.8% over our 
12-week study period is also in line with estimates 
from highly affected areas in other european coun-
tries [2, 5–7]. the slight decrease in seroprevalence 
in the final weeks of our study may be due to several 
factors. One is sampling variation, with previously 
sARs-cov-2-infected individuals likely having a 
higher motivation and fewer reservations to partici-
pate in the study during the lockdown, which took 
place at the beginning of our study. Also, the mail 
recruitment of participants without a known email 
address began in the second month and concerned 
mostly older individuals. however, we now know that 
clusters play an important role in the transmission 
dynamics of cOvID-19 [25]. thus, clustering of the 
cases in the sampled households might help to 
explain this variation. similar observations have been 
made in a large serosurvey in the uk (ReAct2), in 
which the seroprevalence declined from 6.0% to 
4.4% between June and september 2020 [3].
consistent with previous serosurveys [2], our 
study shows a significantly higher risk of infection in 
men (relative risk (RR) 1.22, 95% crI 1.06–1.40) 
than in women. this should be considered when 
reviewing available evidence of increased complica-
tion and mortality rates in men [26]. Regarding age, 
we found higher relative risks of infection in adults of 
working age, teenagers and preadolescents than in 
children and older adults. While advanced age is now 
widely recognised as a risk factor for cOvID-19-
related complications and mortality [27], the rela-
tionship between age and susceptibility to infection 
probably depends on multiple factors. An immuno-
logical cause cannot be excluded at this stage. 
however, our study, like other serosurveys, was con-
ducted in part during a lockdown. As such, it is likely 
that the measures in place affected adults, children 
and the elderly differently. the latter could have 
adopted and applied social isolation and preventive 
measures more strictly out of fear of suffering from 
Figure 1. Age-stratified univariate odds ratios of seropositivity according to symptoms. error bars correspond to 95% confidence intervals 
of odds ratios.
systemic symptoms: presence of either fatigue, myalgia, arthralgia or loss of appetite.
upper airways symptoms: presence of either sneezing/rhinorrhea, sore throat or both.
Digestive symptoms: one or more of abdominal pain, nausea/vomiting and diarrhoea.
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severe complications, resulting in a decreased infec-
tion rate. Also, school closures may have contributed 
to the low seroprevalence observed in young children 
in our study, although recent household analyses 
based on our data suggest that children may be at 
reduced risk of infection even if exposed [28]. Adults 
of working age, on the other hand, could have had 
difficulty effectively socially distancing, as they were 
likely to be the ones to do grocery shopping and 
other tasks requiring them to leave the house. they 
might also have been essential workers, as evidenced 
by the fact that only a minority of participants 
(43.0%) reported working remotely since the begin-
ning of the pandemic.
Odds of seropositivity were significantly reduced 
for retired women and unemployed men compared 
to employed women and men, respectively, adjusting 
for age. seroprevalence was also lower, although with 
borderline significance, for all retired and unem-
ployed individuals. these individuals could have had 
more flexibility in their daily routine allowing them 
to self-isolate better during the epidemic. While edu-
cational level was not significantly associated with the 
risk of infection, we did see trends of this association, 
except for doctoral-level education. It might be diffi-
cult to detect significant differences in the risk associ-
ated with educational level because it is linked to the 
profession of individuals in each educational level, 
which can be quite heterogenous. Finally, no signifi-
cant association was found between median living 
area-based income and sARs-cov-2 seropositivity.
similar to previous reports, we found that current 
smokers were less likely to be seropositive [5]. several 
hypotheses exist, including the effects of smoking on 
the expression of the angiotensin-converting enzyme 
2 receptor in cells of the respiratory tract and the 
competition between nicotine and sARs-cov-2 for 
the nicotinic acetylcholine receptor (nAcfR), which 
acts as a co-receptor for viral cell entry [29]. Further 
work is needed to understand the behaviours that 
may contribute to this association, such as potential 
risk-averting behaviour in smokers out of a fear of 
respiratory complications of cOvID-19.
confirming previous reverse transcriptase poly-
merase chain reaction (rt-PcR)-based studies [30], 
in our sample, anosmia was frequently reported in 
seropositive (44%) but rarely in seronegative par-
ticipants (3%), with individuals reporting this 
symptom being almost 25 times more likely to be 
seropositive than those who did not. however, as 
previously reported [31, 32], the correlation was 
weaker among individuals aged 65 years and older, 
possibly because the senses of taste and smell tend 
to decrease with age, thus making the symptom less 
discriminant [33, 34].
A recent meta-analysis based on rt-PcR diagnosis 
estimated the proportion of asymptomatic individu-
als infected with sARs-cov-2 to be 20% (95% cI 
17–25%), with a prediction interval of 3–67% [35]. 
however, due to the short window of the relatively 
high sensitivity of rt-PcR, it fails to capture all 
asymptomatic individuals. Also, individuals consid-
ered asymptomatic at the time of rt-PcR are poten-
tially just presymptomatic [36]. serological data 
mostly elude these difficulties if the delay between 
symptoms and testing is long enough. In our sample, 
13% of IgG-positive individuals reported being 
asymptomatic. however, the number of participants 
with an asymptomatic sARs-cov-2 infection in our 
sample is likely to be underestimated. Indeed, as the 
question referred to multiple past symptomatic epi-
sodes, it is possible that some of the symptoms 
reported by seropositive participants were non-
sARs-cov-2 related. Of note, 57% of seronegative 
participants reported one or more symptoms.
Our study found some age-related differences in 
terms of clinical presentation. In individuals younger 
than 18 years, only fever, cough and systemic symp-
toms were associated with seropositivity, whereas in 
adults, all symptom groups were significantly associ-
ated with seropositivity. Also, while being asympto-
matic reduced the odds of seropositivity almost 
fivefold in the overall study population, odds were 
only twice reduced in children, with a higher percent-
age of asymptomatic positive children than positive 
adults (37% vs. 10%, supplemental table 11). Future 
serosurveys may be warranted in the context of new 
prevaling sARs-cov-2 variants, in order to assess 
their impact on cOvID-19 clinical presentation.
Our study comes with a number of limitations. 
the Bus santé source population originally con-
tained individuals between 20 and 74 years old, 
explaining the lower number of participants aged less 
than 18 and over 75 years in our final sample, despite 
the inclusion of primary participants’ household 
members. efforts were made to increase the propor-
tion of elderly individuals in our sample by offering 
home visits to those who were physically unable to 
travel to the testing centre or who preferred not to 
leave their homes because of their vulnerability to 
sARs-cov-2. however, this population is still 
underrepresented in our sample. Also, the institu-
tionalised older population was not included in the 
study. Furthermore, it is possible that individuals 
who believed they had been infected may have been 
more likely to participate, especially in early phases 
of the study, leading to a risk of selection bias. the 
seemingly low participation rate of 42% is a common 
issue in population-based surveys which do not use 
convenience samples (e.g. blood donors). Other 
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sARs-cov-2 serosurveys in high-income countries 
using a general population random sampling design 
have resulted in similar participation rates ranging 
from 19.5% to 53% [37–40]. Due to the urgent con-
text in which the study took place during the first 
pandemic wave, our assessment of socioeconomic 
position was based on the most common indicators 
used, such as occupation and education [41, 42]. 
Further research should conduct more detailed anal-
yses taking into account indicators better tailored to 
specific age groups (e.g. wealth, household condi-
tions or parents’ education). Further, the association 
of income level with a seropositive status could not 
be assessed in the same manner as other socioeco-
nomic factors, as we did not collect individual par-
ticipants’ income, but estimated it based on their 
place of residency. One additional limitation was the 
large number of associations tested. Although this 
was not adjusted for, most significant associations 
held at P values less than 0.001. memory bias likely 
influenced symptoms analysis, as participants were 
asked to report symptoms having occurred up to 6 
months earlier. Also, some of the symptoms reported 
by IgG-positive participants may have been caused 
by other pathogens, as 1644 participants reported 
multiple episodes. Finally, the severity of the disease 
was not addressed in this study.
Conclusions
Our study determined that the average seropreva-
lence of sARs-cov-2 in the canton of Geneva over 
the course of the first wave was 7.8 %, leaving most 
of the population naive to the virus. Our risk factor 
analysis indicates that while some socioeconomic dis-
parities in susceptibility to the infection do exist, they 
are likely to be more complex than what we previ-
ously thought. Older individuals seemed to be pro-
tected from infection during the first wave, perhaps 
due to targeted preventive measures. some impor-
tant observations could be made regarding differ-
ences in symptoms among age groups, such as the 
proportion of asymptomatic infections. however, 
future serosurveys should focus on larger samples of 
young children and the elderly to yield more detailed 
age-specific results regarding symptoms.
the results of our study can help inform global 
policy-makers as to how population immunity evolved 
after the first wave of cOvID-19 in a highly affected 
area. Assuming similar preventive measures are kept in 
place, our results suggest that it will likely take time to 
reach herd immunity without risking the collapse of 
health systems. moreover, this article adds to the still 
modest evidence base on risk factors for sARs-cov-2 
infection, and thus can help target public health 
interventions. Finally, the study of symptoms is an 
important step to refine diagnostic criteria and assist 
clinicians in their fight against the pandemic.
As sufficient vaccination of the population will 
likely take time, repeated seroprevalence surveys will 
be crucial to monitor the progression of the epidemic. 
Following up seropositive individuals will allow for 
determining the extent of the immune protection con-
ferred by specific antibodies against re-infection by 
sARs-cov-2, as well as provide insight into the prev-
alence of ‘long cOvID’. Also, better characterisation 
of the sociodemographic risk factors for infection is 
needed to improve prevention strategies further. these 
measures will be of paramount importance to guide 
public health policy in order to manage future out-
breaks of cOvID-19 effectively.
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